LONSURF®, Receives

Servier and its partner Taiho Pharmaceutical Co., Ltd announced today that the European Commission (EC) has approved the use of LONSURF® (trifluridine / tipiracil) as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

06.09.2019 - 08:01:40

LONSURF® Receives Marketing Authorization in Europe for Patients With Previously Treated Metastatic Gastric Cancer

Last accessed August 2019.

2. Bernards N, Creemers GJ, Nieuwenhuijzen GA, et al. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol. 2013;24:3056–60.

3. European Medicines Agency. LONSURF European public assessment report. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf. Last accessed August 2019.

4. World Health Organisation. Globocan (2018), gastric cancer. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf. Last accessed August 2019.

@ businesswire.com